Company

NervGen Pharma Corp

Headquarters: Vancouver, BC, Canada

CEO: Mr. Paul Anthony Brennan B.Sc., M.Sc.

TSXV: NGEN -1.75%

Market Cap

C$228.0 Million

CAD as of July 1, 2024

US$166.0 Million

Market Cap History

NervGen Pharma Corp market capitalization over time

Evolution of NervGen Pharma Corp market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of NervGen Pharma Corp

Detailed Description

NervGen Pharma Corp., a clinical stage biotech company, discovers and develops treatments for patients suffering from medical conditions related to nerve damage. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

NervGen Pharma Corp has the following listings and related stock indices.


Stock: TSXV: NGEN wb_incandescent

Stock: OTC: NGENF wb_incandescent

Details

Headquarters:

Three Bentall Centre

Suite 1703 595 Burrard Street

Vancouver, BC V7X 1J1

Canada

Phone: 604 488 5421